Literature DB >> 18619377

New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.

Bruce D Cheson1.   

Abstract

The International Harmonization Project developed recommendations for the use of positron emission tomography (PET) in managing patients who have lymphoma. It provided guidance as to the interpretation of fluorodeoxyglucose (FDG) PET and generated response definitions, incorporating metabolic imaging with the goal of improving interpretation of response and comparability among studies, leading to accelerated new agent development, more rapid availability of more effective therapies, and the enhancement of outcome for patients with lymphoma.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18619377     DOI： 10.1016/j.rcl.2008.03.003

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN： 0033-8389            Impact factor:   2.303


  13 in total

1.  High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma.

Authors:  Dai Chihara; Yasuhiro Oki; Hiroshi Onoda; Hirofumi Taji; Kazuhito Yamamoto; Tsuneo Tamaki; Yasuo Morishima
Journal:  Int J Hematol       Date:  2011-04-06       Impact factor: 2.490

2.  Early [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report.

Authors:  Peter D Cole; Kathleen M McCarten; Richard A Drachtman; Pedro de Alarcon; Lu Chen; Tanya M Trippett; Cindy L Schwartz
Journal:  Pediatr Hematol Oncol       Date:  2010-11       Impact factor: 1.969

3.  A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.

Authors:  Terzah M Horton; Richard A Drachtman; Lu Chen; Peter D Cole; Kathleen McCarten; Stephan Voss; Robert P Guillerman; Allen Buxton; Scott C Howard; Shirley M Hogan; Andrea M Sheehan; Dolores López-Terrada; Matthew D Mrazek; Neeraj Agrawal; Meng-Fen Wu; Hao Liu; Pedro A De Alarcon; Tanya M Trippet; Cindy L Schwartz
Journal:  Br J Haematol       Date:  2015-04-01       Impact factor: 6.998

4.  On the prediction of Hodgkin lymphoma treatment response.

Authors:  E J deAndrés-Galiana; J L Fernández-Martínez; O Luaces; J J Del Coz; R Fernández; J Solano; E A Nogués; Y Zanabilli; J M Alonso; A R Payer; J M Vicente; J Medina; F Taboada; M Vargas; C Alarcón; M Morán; A González-Ordóñez; M A Palicio; S Ortiz; C Chamorro; S Gonzalez; A P González-Rodríguez
Journal:  Clin Transl Oncol       Date:  2015-04-21       Impact factor: 3.405

5.  Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma.

Authors:  Veronika Bachanova; Ryan Shanley; Farhana Malik; Lata Chauhan; Vishal Lamba; Daniel J Weisdorf; Linda J Burns; Jatinder Kaur Lamba
Journal:  Biol Blood Marrow Transplant       Date:  2015-02-10       Impact factor: 5.742

6.  Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.

Authors:  Veronika Bachanova; Arthur E Frankel; Qing Cao; Dixie Lewis; Bartosz Grzywacz; Michael R Verneris; Celalettin Ustun; Aleksandr Lazaryan; Brian McClune; Erica D Warlick; Hagop Kantarjian; Daniel J Weisdorf; Jeffrey S Miller; Daniel A Vallera
Journal:  Clin Cancer Res       Date:  2015-03-15       Impact factor: 12.531

7.  Automated tracking of quantitative assessments of tumor burden in clinical trials.

Authors:  Daniel L Rubin; Debra Willrett; Martin J O'Connor; Cleber Hage; Camille Kurtz; Dilvan A Moreira
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

8.  Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma.

Authors:  Mateja Horvat; Barbara Jezersek Novakovic
Journal:  Radiol Oncol       Date:  2010-10-14       Impact factor: 2.991

9.  Improvement of hospital care for patients with non-Hodgkin's lymphoma: protocol for a cluster randomized controlled trial (PEARL study).

Authors:  Jozette J C Stienen; Rosella P M G Hermens; Lianne Wennekes; Saskia A M van de Schans; Helena M Dekker; Nicole M A Blijlevens; Richard W M van der Maazen; Eddy M M Adang; Johan H J M van Krieken; Petronella B Ottevanger
Journal:  Implement Sci       Date:  2013-07-09       Impact factor: 7.327

10.  The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice.

Authors:  Brigita Gregoric; Vesna Zadnik; Barbara Jezersek Novakovic
Journal:  Radiol Oncol       Date:  2012-01-02       Impact factor: 2.991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.